APPYEA, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that APPYEA, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2019 | $345 | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | $4.2K | Oct 18, 2019 |
| FY2016 | Jun 30, 2016 | $6.1K | Sep 30, 2016 |
| FY2016 | Jun 30, 2015 | $4.0K | Sep 30, 2016 |
| FY2015 | Jun 30, 2014 | $7.7K | Oct 28, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.0K | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $29.0K | Apr 16, 2026 |
| FY2018 | Jun 30, 2018 | $4.2K | Oct 15, 2018 |
| FY2018 | Jun 30, 2017 | $995 | Oct 15, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.0K) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $14.0K | Apr 16, 2026 |
| FY2016 | Jun 30, 2016 | $6.1K | Sep 30, 2016 |
| FY2016 | Jun 30, 2015 | $3.0K | Sep 30, 2016 |
| FY2015 | Jun 30, 2014 | $7.7K | Oct 28, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.10M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($4.03M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.82M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.30M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.18M) | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | ($1.06M) | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | ($1.99M) | Oct 18, 2019 |
| FY2018 | Jun 30, 2017 | ($700.3K) | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | ($2.94M) | Oct 13, 2017 |
| FY2016 | Jun 30, 2015 | ($1.02M) | Sep 30, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.06M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($1.82M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.64M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($2.16M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($718.0K) | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | ($163.9K) | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | ($632.1K) | Oct 18, 2019 |
| FY2018 | Jun 30, 2017 | ($545.8K) | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | ($2.02M) | Oct 13, 2017 |
| FY2016 | Jun 30, 2015 | ($874.3K) | Sep 30, 2016 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.0K | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $339.0K | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $124.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $129.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $81.0K | Mar 31, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($606.0K) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($785.0K) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($597.0K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($595.0K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($168.0K) | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | ($102.3K) | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | ($135.6K) | Oct 18, 2019 |
| FY2018 | Jun 30, 2017 | ($270.7K) | Oct 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $3.0K | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.73M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $385.0K | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $474.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $205.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $506.0K | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | $54.6K | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | $54.5K | Oct 18, 2019 |
| FY2018 | Jun 30, 2017 | $81.6K | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $101.4K | Oct 13, 2017 |
| FY2016 | Jun 30, 2015 | $1.58M | Sep 30, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.80M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $4.53M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $3.03M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.77M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.94M | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | $1.03M | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | $1.90M | Oct 18, 2019 |
| FY2018 | Jun 30, 2017 | $496.8K | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $38.5K | Oct 13, 2017 |
| FY2016 | Jun 30, 2015 | $236.7K | Sep 30, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.95M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($4.13M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($2.54M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($2.55M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.42M) | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | ($975.6K) | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | ($1.85M) | Oct 18, 2019 |
| FY2019 | Jun 30, 2017 | ($415.2K) | Oct 18, 2019 |
| FY2018 | Jun 30, 2016 | $62.9K | Oct 15, 2018 |
| FY2017 | Jun 30, 2015 | $1.34M | Oct 13, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.46M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($10.36M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($6.33M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($4.51M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.21M) | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | ($7.84M) | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | ($6.78M) | Oct 18, 2019 |
| FY2018 | Jun 30, 2017 | ($4.78M) | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | ($4.08M) | Oct 13, 2017 |
| FY2016 | Jun 30, 2015 | ($1.14M) | Sep 30, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $408.0K | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $79.0K | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $222.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $60.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $206.0K | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | $45.1K | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | $47.2K | Oct 18, 2019 |
| FY2019 | Jun 30, 2017 | $42.6K | Oct 18, 2019 |
| FY2018 | Jun 30, 2016 | $14.6K | Oct 15, 2018 |
| FY2017 | Jun 30, 2015 | $265 | Oct 13, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 856.65M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | 521.13M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | 328.84M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 220.93M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 218.25M | Mar 31, 2023 |
| FY2019 | Jun 30, 2019 | 5.10B | Oct 18, 2019 |
| FY2019 | Jun 30, 2018 | 1.24B | Oct 18, 2019 |
| FY2018 | Jun 30, 2017 | 519.97M | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | 464.67M | Oct 13, 2017 |
| FY2016 | Jun 30, 2015 | 37.85M | Sep 30, 2016 |